Koninklijke Philips (NYSE:PHG) Stock Rating Upgraded by UBS Group

Koninklijke Philips (NYSE:PHG) was upgraded by equities research analysts at UBS Group from a “sell” rating to a “neutral” rating in a research report issued to clients and investors on Tuesday, MarketBeat.com reports.

A number of other research analysts also recently weighed in on the stock. BNP Paribas downgraded shares of Koninklijke Philips from an “outperform” rating to an “underperform” rating in a research report on Wednesday, February 7th. JPMorgan Chase & Co. upgraded Koninklijke Philips from an “underweight” rating to a “neutral” rating in a research report on Tuesday. Finally, StockNews.com upgraded Koninklijke Philips from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $19.00.

Koninklijke Philips Trading Up 0.8 %

Shares of NYSE:PHG opened at $26.78 on Tuesday. The company has a current ratio of 1.20, a quick ratio of 0.78 and a debt-to-equity ratio of 0.58. Koninklijke Philips has a 12-month low of $17.75 and a 12-month high of $29.44. The business has a 50 day moving average of $20.83 and a two-hundred day moving average of $21.09. The company has a market capitalization of $24.86 billion, a PE ratio of -27.89, a PEG ratio of 1.38 and a beta of 0.88.

Koninklijke Philips (NYSE:PHG) last posted its earnings results on Monday, January 29th. The technology company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.03. Koninklijke Philips had a negative net margin of 4.41% and a positive return on equity of 9.82%. The firm had revenue of $5.45 billion during the quarter, compared to analysts’ expectations of $5.47 billion. As a group, analysts forecast that Koninklijke Philips will post 1.53 EPS for the current year.

Hedge Funds Weigh In On Koninklijke Philips

Several hedge funds and other institutional investors have recently modified their holdings of PHG. Cambridge Investment Research Advisors Inc. grew its stake in Koninklijke Philips by 3.2% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 22,616 shares of the technology company’s stock valued at $451,000 after acquiring an additional 696 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Koninklijke Philips by 19.4% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 12,679 shares of the technology company’s stock worth $253,000 after purchasing an additional 2,059 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Koninklijke Philips by 21.9% in the third quarter. Bank of New York Mellon Corp now owns 114,019 shares of the technology company’s stock valued at $2,274,000 after purchasing an additional 20,499 shares in the last quarter. Advisor Partners II LLC acquired a new stake in shares of Koninklijke Philips in the third quarter valued at approximately $252,000. Finally, Assetmark Inc. increased its holdings in shares of Koninklijke Philips by 1.1% in the third quarter. Assetmark Inc. now owns 99,435 shares of the technology company’s stock valued at $1,983,000 after purchasing an additional 1,068 shares during the last quarter. 13.67% of the stock is owned by hedge funds and other institutional investors.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.